Azalea Therapeutics Secures $82M in Series A Funding Led by Third Rock Ventures

Why It Matters

The funding validates the emerging in‑vivo gene‑editing CAR‑T model, which could dramatically lower production costs and broaden access to cellular therapies across oncology and autoimmunity. Successful execution would position Azalea as a pioneer in next‑generation precision medicines, reshaping the competitive landscape of cell‑based therapeutics.

Deal Summary

Azalea Therapeutics announced the completion of an $82 million seed and Series A financing round, with a $65 million Series A led by Third Rock Ventures. The round also included participation from RA Capital Management, Yosemite, Sozo Ventures and individual investors. The capital will fund the development of its in‑vivo CAR‑T therapies and expand its genome‑editing platform.